Mangoceuticals (NASDAQ:MGRX – Get Free Report) and Chemed (NYSE:CHE – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, dividends, risk, institutional ownership and valuation.
Volatility & Risk
Mangoceuticals has a beta of 2.04, indicating that its stock price is 104% more volatile than the S&P 500. Comparatively, Chemed has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500.
Profitability
This table compares Mangoceuticals and Chemed’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Mangoceuticals | -4,794.60% | -96.39% | -89.60% |
| Chemed | 10.60% | 31.77% | 18.90% |
Institutional & Insider Ownership
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Mangoceuticals and Chemed, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Mangoceuticals | 1 | 0 | 0 | 0 | 1.00 |
| Chemed | 0 | 5 | 1 | 0 | 2.17 |
Chemed has a consensus price target of $530.75, suggesting a potential upside of 5.49%. Given Chemed’s stronger consensus rating and higher probable upside, analysts clearly believe Chemed is more favorable than Mangoceuticals.
Earnings and Valuation
This table compares Mangoceuticals and Chemed”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Mangoceuticals | $315,227.00 | 32.36 | -$20.64 million | ($1.01) | -0.47 |
| Chemed | $2.60 billion | 2.53 | $265.24 million | $19.91 | 25.27 |
Chemed has higher revenue and earnings than Mangoceuticals. Mangoceuticals is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks.
Summary
Chemed beats Mangoceuticals on 11 of the 14 factors compared between the two stocks.
About Mangoceuticals
Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.
About Chemed
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees. The company was incorporated in 1970 and is headquartered in Cincinnati, Ohio.
Receive News & Ratings for Mangoceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mangoceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
